115 related articles for article (PubMed ID: 14760077)
1. Microsatellite instability predicts poor short-term survival in patients with advanced breast cancer after high-dose chemotherapy and autologous stem-cell transplantation.
Wild PJ; Reichle A; Andreesen R; Röckelein G; Dietmaier W; Rüschoff J; Blaszyk H; Hofstädter F; Hartmann A
Clin Cancer Res; 2004 Jan; 10(2):556-64. PubMed ID: 14760077
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation.
Nieto Y; Cagnoni PJ; Nawaz S; Shpall EJ; Yerushalmi R; Cook B; Russell P; McDermit J; Murphy J; Bearman SI; Jones RB
J Clin Oncol; 2000 May; 18(10):2070-80. PubMed ID: 10811672
[TBL] [Abstract][Full Text] [Related]
3. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
Kim YS; Konoplev SN; Montemurro F; Hoy E; Smith TL; Rondón G; Champlin RE; Sahin AA; Ueno NT
Clin Cancer Res; 2001 Dec; 7(12):4008-12. PubMed ID: 11751494
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite instability at chromosome 8p in non-small cell lung cancer is associated with lymph node metastasis and squamous differentiation.
Woenckhaus M; Stoehr R; Dietmaier W; Wild PJ; Zieglmeier U; Foerster J; Merk J; Blaszyk H; Pfeifer M; Hofstaedter F; Hartmann A
Int J Oncol; 2003 Nov; 23(5):1357-63. PubMed ID: 14532977
[TBL] [Abstract][Full Text] [Related]
5. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
Bewick M; Chadderton T; Conlon M; Lafrenie R; Morris D; Stewart D; Glück S
Bone Marrow Transplant; 1999 Aug; 24(4):377-84. PubMed ID: 10467326
[TBL] [Abstract][Full Text] [Related]
6. Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation.
Bewick M; Conlon M; Parissenti AM; Lee H; Zhang L; Glück S; Lafrenie RM
J Hematother Stem Cell Res; 2001 Dec; 10(6):759-68. PubMed ID: 11798502
[TBL] [Abstract][Full Text] [Related]
7. Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer.
Bataille F; Rümmele P; Dietmaier W; Gaag D; Klebl F; Reichle A; Wild P; Hofstädter F; Hartmann A
Mol Pathol; 2003 Oct; 56(5):286-92. PubMed ID: 14514923
[TBL] [Abstract][Full Text] [Related]
8. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer.
Burger M; Denzinger S; Hammerschmied CG; Tannapfel A; Obermann EC; Wieland WF; Hartmann A; Stoehr R
J Mol Med (Berl); 2006 Oct; 84(10):833-41. PubMed ID: 16924473
[TBL] [Abstract][Full Text] [Related]
9. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability.
Gafà R; Maestri I; Matteuzzi M; Santini A; Ferretti S; Cavazzini L; Lanza G
Cancer; 2000 Nov; 89(10):2025-37. PubMed ID: 11066042
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite instability and p53 mutations in sporadic right and left colon carcinoma: different clinical and molecular implications.
Lleonart ME; García-Foncillas J; Sánchez-Prieto R; Martín P; Moreno A; Salas C; Ramón y Cajal S
Cancer; 1998 Sep; 83(5):889-95. PubMed ID: 9731891
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
12. p53 expression is decreased in primary breast carcinomas with microsatellite instability.
Pizzi C; Panico L; De Marchis L; Mastranzo P; Di Maio M; D'Amico C; Limite G; Pettinato G; Cocozza S; Bianco AR; Contegiacomo A
Breast Cancer Res Treat; 2002 Jun; 73(3):257-66. PubMed ID: 12160331
[TBL] [Abstract][Full Text] [Related]
13. Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy.
Schneeweiss A; Goerner R; Hensel MA; Lauschner I; Sinn P; Kaul S; Egerer G; Beldermann F; Geberth M; Solomayer E; Grischke EM; Haas R; Ho AD; Bastert G
Biol Blood Marrow Transplant; 2001; 7(6):332-42. PubMed ID: 11464976
[TBL] [Abstract][Full Text] [Related]
14. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support.
Hensel M; Schneeweiss A; Sinn HP; Egerer G; Solomayer E; Haas R; Bastert G; Ho AD
Int J Cancer; 2002 Jul; 100(3):290-6. PubMed ID: 12115543
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
16. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
17. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.
Isola J; Visakorpi T; Holli K; Kallioniemi OP
J Natl Cancer Inst; 1992 Jul; 84(14):1109-14. PubMed ID: 1352359
[TBL] [Abstract][Full Text] [Related]
18. Low-level microsatellite instability phenotype in sporadic glioblastoma multiforme.
Martinez R; Schackert HK; Appelt H; Plaschke J; Baretton G; Schackert G
J Cancer Res Clin Oncol; 2005 Feb; 131(2):87-93. PubMed ID: 15672285
[TBL] [Abstract][Full Text] [Related]
19. Loss of hMSH2 expression in primary breast cancer with p53 alterations.
Spagnoletti I; Pizzi C; Galietta A; Di Maio M; Mastranzo P; Daniele S; Limite G; Pettinato G; Contegiacomo A
Oncol Rep; 2004 Apr; 11(4):845-51. PubMed ID: 15010883
[TBL] [Abstract][Full Text] [Related]
20. [Microsatellite instability and allele-specific chromosome 3p deletion in breast cancer and precancerous lesions].
Fu Q; Yao GY; Tang XL; Chen LR; Zheng ZX
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):34-40. PubMed ID: 17575691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
